Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306 ; day:23 ; month:7 ; year:2022 ; pages:1-10
British journal of cancer ; (23.7.2022), 1-10
- Urheber
-
Tanaka, Kazuhiro
Machida, Ryunosuke
Kawai, Akira
Nakayama, Robert
Tsukushi, Satoshi
Asanuma, Kunihiro
Matsumoto, Yoshihiro
Hiraga, Hiroaki
Hiraoka, Koji
Watanuki, Munenori
Yonemoto, Tsukasa
Abe, Satoshi
Katagiri, Hirohisa
Nishida, Yoshihiro
Nagano, Akihito
Suehara, Yoshiyuki
Kawashima, Hiroyuki
Kawano, Masanori
Morii, Takeshi
Hatano, Hiroshi
Toguchida, Junya
Okuma, Tomotake
Takeyama, Masanobu
Takenaka, Satoshi
Akisue, Toshihiro
Furuta, Taisuke
Emori, Makoto
Hiruma, Toru
Outani, Hidetatsu
Yamamoto, Tetsuji
Kataoka, Tomoko
Fukuda, Haruhiko
Ozaki, Toshifumi
Iwamoto, Yukihide
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-022-01912-5
- URN
-
urn:nbn:de:101:1-2022100519042051365102
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tanaka, Kazuhiro
- Machida, Ryunosuke
- Kawai, Akira
- Nakayama, Robert
- Tsukushi, Satoshi
- Asanuma, Kunihiro
- Matsumoto, Yoshihiro
- Hiraga, Hiroaki
- Hiraoka, Koji
- Watanuki, Munenori
- Yonemoto, Tsukasa
- Abe, Satoshi
- Katagiri, Hirohisa
- Nishida, Yoshihiro
- Nagano, Akihito
- Suehara, Yoshiyuki
- Kawashima, Hiroyuki
- Kawano, Masanori
- Morii, Takeshi
- Hatano, Hiroshi
- Toguchida, Junya
- Okuma, Tomotake
- Takeyama, Masanobu
- Takenaka, Satoshi
- Akisue, Toshihiro
- Furuta, Taisuke
- Emori, Makoto
- Hiruma, Toru
- Outani, Hidetatsu
- Yamamoto, Tetsuji
- Kataoka, Tomoko
- Fukuda, Haruhiko
- Ozaki, Toshifumi
- Iwamoto, Yukihide
- SpringerLink (Online service)
Ähnliche Objekte (12)
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel
Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel
Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel
Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma